A couple of the slides GK presented at the EGM point to the differences between the trials - the comparisons indicate the patients in the Lupin trial were 'no less advanced' in terms of their cancer vs the WARMTH study.
The 19.7 MOs has the chance to improve as further data is collected up until October this year.
GK also hinted at the potential to go up to 2400mg dosage in future trials .
He also indicated that he is "very comfortable" with the IP situation as the increasing data set allows for claims which a far more novel & inventive versus the initial patents lodged.
Add to My Watchlist
What is My Watchlist?
